At the dawn of the financial crisis in Greece, a group of 14 researchers and clinicians realized the need to struggle to maintain a high level of research and education for sepsis and systemic inflammation that are the main disorders leading to death in our world. This group inaugurated in July 2010 the Hellenic Institute for the Study of Sepsis (HISS), a nonprofit, non-commercial organization.
Find out how it all started
The last eleven years, the Executive Board and the General Assembly are proud to present a very vivid workload summarized as a) continuing support to the investigators of the Hellenic Sepsis Study Group; b) continuing education in sepsis by the organization of thirteen national and international workshops and conferences and by the publications of Greek guidelines in sepsis; c) fifteen completed clinical studies and ten ongoing clinical studies in Greece; four of the clinical trials are international with other European Countries; d) support of PhD theses in sepsis; and e) 72 original publications in international peer-reviewed medical journals.
HISS is pioneer in personalized medicine and is presenting as major achievement the design, conduct, analysis and publication of the double-blind, pivotal trial SAVE-MORE for the successful management of moderate to severe COVID-19 pneumonia with anakinra guided by the biomarker suPAR. This trial was conducted in 37 study sites in Greece and Italy; 606 patients were enrolled and the study received advice from COVID-ETF of the European Medicines Agency.
